JP2022510962A - クレノラニブ併用療法 - Google Patents

クレノラニブ併用療法 Download PDF

Info

Publication number
JP2022510962A
JP2022510962A JP2021531115A JP2021531115A JP2022510962A JP 2022510962 A JP2022510962 A JP 2022510962A JP 2021531115 A JP2021531115 A JP 2021531115A JP 2021531115 A JP2021531115 A JP 2021531115A JP 2022510962 A JP2022510962 A JP 2022510962A
Authority
JP
Japan
Prior art keywords
cancer
clenoranib
weeks
per day
axitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510962A5 (https=
Inventor
ビナイ・ケイ・ジャイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Publication of JP2022510962A publication Critical patent/JP2022510962A/ja
Publication of JP2022510962A5 publication Critical patent/JP2022510962A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021531115A 2018-12-13 2019-12-13 クレノラニブ併用療法 Pending JP2022510962A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862779128P 2018-12-13 2018-12-13
US62/779,128 2018-12-13
US201962861424P 2019-06-14 2019-06-14
US62/861,424 2019-06-14
US16/713,935 2019-12-13
US16/713,935 US11602533B2 (en) 2018-12-13 2019-12-13 Crenolanib combination therapy
PCT/US2019/066308 WO2020123991A1 (en) 2018-12-13 2019-12-13 Crenolanib combination therapy

Publications (2)

Publication Number Publication Date
JP2022510962A true JP2022510962A (ja) 2022-01-28
JP2022510962A5 JP2022510962A5 (https=) 2022-12-20

Family

ID=69596002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531115A Pending JP2022510962A (ja) 2018-12-13 2019-12-13 クレノラニブ併用療法

Country Status (5)

Country Link
US (2) US11602533B2 (https=)
EP (1) EP3893874A4 (https=)
JP (1) JP2022510962A (https=)
CN (1) CN110840893A (https=)
WO (1) WO2020123991A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
CN113491693B (zh) * 2020-03-19 2023-11-14 江苏恒瑞医药股份有限公司 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途
CA3186319A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
CN118576611A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗尤文氏肉瘤的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014097929A (ja) * 2012-09-21 2014-05-29 Arog Pharmaceuticals Llc 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1641780B1 (en) 2003-06-24 2008-11-12 Pfizer Products Incorporated Processes for the preparation of 1- [(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
US20130230511A1 (en) * 2012-02-03 2013-09-05 Board Of Regents, The University Of Texas System Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
EA039595B1 (ru) 2012-10-05 2022-02-15 Кадмон Корпорейшн, Ллк Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
EP3060654B1 (en) 2013-10-21 2023-03-15 Hemoshear, LLC In vitro model for a tumor microenvironment
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014097929A (ja) * 2012-09-21 2014-05-29 Arog Pharmaceuticals Llc 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU, TIANRUN ET AL., NATURE COMMUNICATIONS, vol. Vol.9, No.1, Article number:3439, JPN6023001241, 27 August 2018 (2018-08-27), pages 1 - 13, ISSN: 0005154172 *
MICHAEL, M ET AL., BRITISH JOURNAL OF CANCER, vol. 103, no. 10, JPN6023001240, 2010, pages 1554 - 1561, ISSN: 0005154173 *
ZIMMERMAN, ERIC I ET AL., BLOOD, vol. 122, no. 22, JPN6023001239, 2013, pages 3607 - 3615, ISSN: 0005154174 *

Also Published As

Publication number Publication date
EP3893874A4 (en) 2022-08-24
WO2020123991A1 (en) 2020-06-18
US20200188385A1 (en) 2020-06-18
CN110840893A (zh) 2020-02-28
EP3893874A1 (en) 2021-10-20
US11602533B2 (en) 2023-03-14
US20230181565A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US20230181565A1 (en) Crenolanib combination therapy
Lazăr et al. New advances in targeted gastric cancer treatment
Syrigos et al. Bevacizumab-induced hypertension: pathogenesis and management
Jeong et al. US FDA approved oral kinase inhibitors for the treatment of malignancies
Roviello et al. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer
JP2021138704A (ja) 神経膠芽腫の治療のための併用療法
Aprile et al. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
KR20240112932A (ko) 암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법
Bitting et al. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma
CN112236147A (zh) 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
KR20220011647A (ko) 소세포폐암의 병용 치료용 퀴놀린 유도체
JP7642556B2 (ja) 併用医薬
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
Boere et al. It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor–vascular endothelial growth factor receptor pathway in patients with solid malignancies
K Koutras et al. Angiogenesis as a therapeutic target in breast cancer
Schvartsman et al. An unusual case of central retinal vein occlusion and review of the toxicity profile of regorafenib in GIST patients
De Jonge et al. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
Cohen et al. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
CN120282786A (zh) 治疗晚期实体肿瘤的方法
HK40017631A (en) Pharmaceutical compositions containing crenolanib and use thereof
CN104968363A (zh) Pi3k/akt抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
V Koukourakis Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question
Wang et al. Polypharmacology in clinical applications—anticancer polypharmacology
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230919